The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
According to the estimates by IMARC Group, the global hormone replacement therapy market is expected to exhibit a CAGR of XX% during 2022-2027
The rising prevalence of hormone imbalance disorders, particularly among the geriatric and neonatal populations, is primarily driving the global market for hormone replacement therapy.
The introduction of innovative drug delivery systems, including new gel-based formulations and estrogen patches, represents one of the key trends in the global hormone replacement therapy market.
Sudden outbreak of the COVID-19 pandemic had led to the limited number of hospital visits for mitigating the risk of coronavirus transmission, thereby hampering the demand for elective hormone replacement therapy across the globe.
On the basis of the product, the market has been bifurcated into estrogen replacement therapy, human growth hormone replacement therapy, testosterone replacement therapy, thyroid replacement therapy, and others. Amongst these, estrogen replacement therapy holds the majority of the total market share.
On the basis of the route of administration, the market has been classified into oral, parenteral, and transdermal segments. At present, parenteral route of administration exhibits a clear dominance in the market.
On the basis of type of disease, the market has been categorized into growth hormone deficiency, hypothyroidism, menopause, male hypogonadism, and others. Currently, menopause accounts for the majority of the total market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at